GSK Neural Pathways Discovery Performance Unit, Singapore Singapore
Research
Date range: 1 November 2022 - 31 October 2023
No articles found. GSK Neural Pathways Discovery Performance Unit, Singapore did not contribute to any primary research papers from Nature Index journals in the current 12 month window.Relationships
GlaxoSmithKline plc. (GSK)
-
↳ GSK Neural Pathways Discovery Performance Unit, Singapore
- Cellzome GmbH
- GSK Vaccines Institute for Global Health Srl
- GlaxoSmithKline (GSK) Jurong
- GlaxoSmithKline AG, Switzerland
- GlaxoSmithKline Australia Pty. Ltd.
- GlaxoSmithKline Belgium
- GlaxoSmithKline France
- GlaxoSmithKline GmbH & Co. KG
- GlaxoSmithKline Ireland
- GlaxoSmithKline Oy
- GlaxoSmithKline Panamá
- GlaxoSmithKline Pharmaceuticals Limited
- GlaxoSmithKline R&D Bangalore
- GlaxoSmithKline R&D China
- GlaxoSmithKline R&D Verona
- GlaxoSmithKline Spain
- GlaxoSmithKline Sweden
- GlaxoSmithKline UAE
- GlaxoSmithKline USA
- GlaxoSmithKline Vaccines (GSK Vaccines)
- GlaxoSmithKline Vaccines Singapore
- Glycovaxyn AG
- Human Genome Sciences, Inc.
- Novartis Vaccines and Diagnostics
- Novartis Vaccines and Diagnostics GmbH
- Novartis Vaccines and Diagnostics, Inc.
- Novartis Vaccines and Diagnostics, Inc. - Cambridge
- Okairos AG
- Sirtris Pharmaceuticals, Inc.
- TESARO, Inc.